Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:03 PM ET 10-Q
Financial Results First Busey Corp BUSE

First Busey Q3 2026 Results: Net Income $55.8M, Down 2.2% YoY

For the third quarter of 2026, First Busey Corporation reported net interest income of $153.1 million and total noninterest income of $40.4 million. The company's balance sheet shows total assets of $18.6 billion, with a notable increase in cash and cash equivalents to $883.1 million compared to $280.2 million at year-end 2025.

Key figure
Net income $55.8M · -2.2% YoY
4:03 PM ET 8-K
Financial Results Bill Holdings, Inc. BILL

Bill Holdings Financial Results

BILL Holdings reported first quarter fiscal 2027 results with total revenue of $353.8 million, up 13% year-over-year, and core revenue of $316.4 million. The company noted a voluntary change in accounting principle effective July 1, 2026, which now classifies card rewards as a reduction of revenue rather than a sales and marketing expense.

Term
Q1 2027

“AI is changing what’s possible for us, and it shows in our product velocity: five new launches this quarter, and a Visa pilot built in four weeks. We’re well positioned to serve the millions of businesses that still need help simplifying their finances.”

René Lacerte, BILL CEO and Founder

“In Q1, we delivered 14% core revenue growth, significantly expanded our operating margin, and achieved a Rule of 40 score of 51. With a durable business model, a leaner organization, and an integrated platform serving a large market, we are focused on executing with discipline.”

Rohini Jain, BILL Chief Financial Officer
4:03 PM ET 10-Q
Financial Results Mach Natural Resources LP MNR ▶ Call

Mach Natural Resources Q3 2026 Results: Turns Profitable, Net Income $10.2M

Mach Natural Resources LP reported 170,395,787 common units outstanding as of October 30, 2026, and is classified as an accelerated filer and an emerging growth company. The filing outlines a transition to a new senior secured revolving credit agreement dated February 27, 2025, and provides definitions for key performance metrics such as Adjusted EBITDA and PV-10.

Key figure
Net income $10.2M
4:03 PM ET 10-Q
Financial Results Adtran Holdings, Inc. ADTN

Adtran Holdings Q3 2026 Results: Net Loss of $9.23M, Loss Narrows

ADTRAN Holdings, Inc. reported 81,495,825 shares of common stock outstanding as of October 31, 2026. The filing highlights significant risks including indebtedness, material weaknesses in internal control over financial reporting, and ongoing inflationary pressures impacting profitability.

Key figure
Net loss $9.23M
4:03 PM ET 8-K
Financial Results Keros Therapeutics, Inc. KROS

Keros Therapeutics Financial Results

Keros Therapeutics reported third quarter 2026 financial results, highlighted by a net income of $14.2 million compared to a net loss in the prior year, primarily due to revenue recognition from its license agreement with Takeda. The company also announced the first patient dosed in its Phase 2 trial of rinvatercept for DMD and expects its $259.5 million cash balance to fund operations into the second half of 2028.

“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients. We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”

Jasbir S. Seehra, Ph.D., President and Chief Executive Officer
4:03 PM ET 8-K
Financial Results Voyager Therapeutics, Inc. VYGR

Voyager Therapeutics Financial Results

Voyager Therapeutics reported third quarter 2026 financial results, ending the period with $132 million in cash and extending its projected runway into Q2 2028. The company highlighted progress in its Alzheimer’s disease pipeline, with clinical data readouts for VY7523 expected in Q4 2026 and patient dosing for VY1706 anticipated in the coming months.

“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months.”

Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager

“During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028. This strengthens our position as we approach key upcoming milestones.”

Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager
4:03 PM ET 8-K
Financial Results Conduent Inc CNDT

Conduent Financial Results

Conduent reported Q3 2026 revenue of $534 million and a net loss of $49 million, while reaffirming its full-year 2026 outlook. The company highlighted progress on its ASCEND transformation plan, identifying $106 million of its $120 million cost-savings target and completing a $447 million revolving credit facility refinancing.

Term
Q3 2026

“In the third quarter, we continued to make progress in improving Conduent’s operating performance. Adjusted EBITDA increased year-over-year and sequentially, and we are reaffirming our full-year 2026 outlook.”

Harsha V. Agadi, Chief Executive Officer

“ASCEND 2026–2028 is our framework for turning this transformation into sustained performance. We are standardizing our operations and infrastructure, specializing in core solutions where we can lead and win, and scaling our go-to-market capabilities around priority industries and opportunities.”

Harsha V. Agadi, Chief Executive Officer
4:03 PM ET 8-K
Financial Results TransMedics Group, Inc. TMDX

TransMedics Group Financial Results

TransMedics reported record third-quarter 2026 revenue of $203.0 million, a 41% increase year-over-year, driven by strong growth in both product and service revenue. The company achieved net income of $17.1 million and raised its full-year 2026 revenue guidance to a range of $764 million to $774 million.

“The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.”

Waleed Hassanein, MD, President and Chief Executive Officer

“We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS.”

Waleed Hassanein, MD, President and Chief Executive Officer
4:03 PM ET 10-Q
Financial Results Expensify, Inc. EXFY ▶ Call

Expensify Q3 2026 Results: Net Loss of $3.33M, Loss Widens

Expensify, Inc. reported total assets of $190.3 million as of September 30, 2026, a slight increase from $186.0 million at the end of 2025. The company maintains a diverse capital structure with Class A, LT10, and LT50 common stock, and is currently classified as an accelerated filer and a smaller reporting company.

Key figure
Net loss $3.33M
4:03 PM ET 8-K
Financial Results Corvus Pharmaceuticals, Inc. CRVS

Corvus Pharmaceuticals Financial Results

Corvus Pharmaceuticals reported third quarter 2026 financial results and provided a business update on its soquelitinib clinical programs. The company ended the quarter with $202.9 million in cash and marketable securities, which is expected to provide a financial runway into the second quarter of 2028.

“We continue to drive the science and advance the breadth of potential clinical indications for ITK inhibition with soquelitinib. Our Phase 3 PTCL and Phase 2 atopic dermatitis clinical trials are on track and there has been strong interest in our new hidradenitis suppurativa trial. We also are making good progress towards initiating a unique asthma trial that will include both T2 and non-T2 patients by Q1 2027. We believe soquelitinib has the potential to be effective in both types of asthma patients based on its mechanism of action affecting Th2, Th17 and T regulatory cells, which we will be closely analyzing in our hidradenitis suppurativa trial. Taken altogether, we are positioned for a series of potentially significant data milestones across our soquelitinib development pipeline in 2027.”

Richard A. Miller, M.D., co-founder, president and chief executive officer
4:03 PM ET 10-Q
Financial Results Verastem, Inc. VSTM

Verastem Q3 2026 Results: Net Loss of $74.7M, Loss Narrows

Verastem reported Q3 2026 net product revenue of $24.0 million, a significant increase from $11.2 million in the prior year, driven by AVMAPKI FAKZYNJA CO-PACK sales. Despite a GAAP net loss of $74.7 million, the company strengthened its balance sheet with a $250 million follow-on offering in October, extending its cash runway into the first half of 2028.

Key figure
Net loss $74.7M
4:02 PM ET 10-Q
Financial Results Power Integrations Inc POWI

Power Integrations Q3 2026 Results: Turns Profitable, Net Income $18.3M

Power Integrations reported net revenue of $125.5 million for the third quarter of 2026, an increase from $118.9 million in the prior year period. The company returned to profitability with a net income of $18.3 million compared to a net loss of $1.4 million in Q3 2025, despite incurring $6.2 million in restructuring charges earlier in the year.

Key figure
Net income $18.3M
4:02 PM ET 10-Q
Financial Results Voyager Therapeutics, Inc. VYGR

Voyager Therapeutics Q3 2026 Results: Net Loss of $24.7M, Loss Narrows

For the nine months ended September 30, 2026, Voyager Therapeutics reported a net loss of $77.1 million, an improvement from the $92.3 million loss in the same period of 2025. Collaboration revenue decreased significantly to $9.8 million from $25.0 million year-over-year, while total assets declined to $177.1 million as of September 30, 2026.

Key figure
Net loss $24.7M
4:02 PM ET 8-K
Financial Results Trupanion, Inc. TRUP

Trupanion Financial Results

Trupanion reported Q3 2026 total revenue of $405.6 million, an increase of 11% year-over-year, and net income of $9.3 million. The company also disclosed the repurchase of approximately $25 million of its common stock during the quarter under its existing $100 million authorization.

Term
Q3 2026

“Our third-quarter results were strong, with record cash flow and increased profitability, the seventh consecutive quarter of improvement in retention, and continued progress on our key strategic initiatives. As our business continues to compound, we are investing with discipline in organic growth, and this quarter we also repurchased approximately $25 million of our stock. Both reflect our confidence in the long-term value we are building for pet parents and shareholders.”

Margi Tooth, Chief Executive Officer and President
4:02 PM ET 10-Q
Financial Results Research Frontiers Inc REFR

Research Frontiers Q3 2026 Results: Net Loss of $510K, Loss Widens

Research Frontiers reported a net loss of $1,695,837 for the nine months ended September 30, 2026, compared to a loss of $1,280,021 in the prior year period. Fee income significantly decreased to $299,706 from $1,049,125, while the company maintained a working capital of approximately $0.5 million following a $1.375 million issuance of common stock and warrants.

Key figure
Net loss $510K
4:02 PM ET 10-Q
Financial Results Sintx Technologies, Inc. SINT

Sintx Technologies Q3 2026 Results: Net Loss of $1.59M, Loss Narrows

Sintx Technologies reported a significant increase in total revenue to $3.0 million for the nine months ended September 30, 2026, compared to $0.7 million in the prior year, primarily driven by product revenue. Despite the revenue growth, the company recorded a net loss of $7.1 million for the period, though this was an improvement from the $8.1 million net loss in the same period of 2025.

Key figure
Net loss $1.59M
4:02 PM ET 10-Q
Financial Results Grayscale Bitcoin Mini Trust ETF BTC

Grayscale Bitcoin Mini Trust ETF Q3 2026 Results: Net Income $1.48B, Up 418.4% YoY

Grayscale Bitcoin Mini Trust ETF reported a net increase in net assets from operations of $1.48 billion for the quarter ended September 30, 2026, primarily driven by $1.48 billion in unrealized appreciation of Bitcoin. As of September 30, 2026, the Trust held 63,087.34 Bitcoin with a fair value of $5.27 billion, representing a significant increase from the $4.24 billion held at year-end 2025.

Key figure
Net income $1.48B · +418.4% YoY
4:02 PM ET 10-Q
Financial Results Sarepta Therapeutics, Inc. SRPT

Sarepta Therapeutics Q3 2026 Results: Net Loss of $28.5M, Loss Narrows

Sarepta Therapeutics reported a net income of $297.6 million for the first nine months of 2026, a significant turnaround from a $301.2 million loss in the prior year period. Total revenues for the nine months reached $1.51 billion, driven by $983.0 million in net product sales and $530.4 million from collaboration and other revenue.

Key figure
Net loss $28.5M
4:02 PM ET 8-K
Financial Results Cardlytics, Inc. CDLX

Cardlytics Financial Results

Cardlytics reported third quarter 2026 financial results with revenue of $32.9 million, a 30% year-over-year decrease. Despite the revenue decline and a net loss of $8.9 million, the company achieved a positive Adjusted EBITDA of $0.4 million and highlighted progress in adding new partners and growing its advertising base.

“Our third quarter results came in below expectations. However, we remain encouraged by the progress towards our priorities. We are building supply by adding new CRP partners and continuing to grow our advertising base.”

Amit Gupta, CEO of Cardlytics

“We are running a leaner business, with lower costs, and a higher contribution margin. We expect sequential growth in the fourth quarter as we work toward self-sustainability.”

David Evans, CFO of Cardlytics
4:02 PM ET 10-Q
Financial Results Interactive Brokers Group, Inc. IBKR

Interactive Brokers Group Q3 2026 Results: Net Income $1.35B, Up 13.7% YoY

Interactive Brokers Group reported net revenues of $1,914 million for the quarter ended September 30, 2026, driven by strong growth in net interest income and commissions. Net income available for common stockholders rose to $314 million, while total assets increased to $243.2 billion compared to $203.2 billion at the end of 2025.

Key figure
Net income $1.35B · +13.7% YoY
4:02 PM ET 10-Q
Financial Results Epam Systems, Inc. EPAM

Epam Systems Q3 2026 Results: Net Income $130M, Up 22.0% YoY

EPAM Systems reported revenues of $1.43 billion for the third quarter of 2026, a 2.3% increase compared to the same period in 2025. Net income for the nine months ended September 30, 2026, rose to $315.8 million from $268.3 million in the prior year, while the company significantly reduced its share count through $488.3 million in common stock repurchases during the first nine months of 2026.

Key figure
Net income $130M · +22.0% YoY
4:02 PM ET 10-Q
Financial Results Magnolia Oil & Gas Corp MGY ▶ Call

Magnolia Oil & Gas Q3 2026 Results: Net Income $80.5M, Up 6.7% YoY

Magnolia Oil & Gas reported a significant expansion in Q3 2026, driven by the $1.2 billion WildFire Acquisition and a public offering of common stock. Total assets grew from $2.9 billion to $7.4 billion year-to-date, while net income for the nine months ended September 30, 2026, rose to $363.1 million compared to $265.9 million in the prior year period.

Key figure
Net income $80.5M · +6.7% YoY
4:02 PM ET 8-K
Financial Results Omada Health, Inc. OMDA

Omada Health Financial Results

Omada Health reported Q3 2026 revenue of $91 million, a 34% year-over-year increase, and reached a record 1.1 million total members. The company achieved GAAP net income of $7 million compared to a loss in the prior year and raised its full-year 2026 revenue and Adjusted EBITDA guidance.

Term
Q3 2026

“Omada Health delivered its strongest quarter yet, with revenue growing 34% year over year, Total Members increasing 36% and a GAAP gross margin of 76%. Our diabetes and hypertension programs led that growth, and average tenure in our programs reached a record of roughly two years and four months. That gives members more time to build lasting habits and the confidence to manage their health.”

Sean Duffy, co-founder and CEO of Omada Health
4:02 PM ET 8-K
Financial Results Celldex Therapeutics, Inc. CLDX

Celldex Therapeutics Financial Results

Celldex Therapeutics reported third quarter 2026 financial results and provided a corporate update on its barzolvolimab program. The company highlighted positive Phase 3 topline results in chronic spontaneous urticaria (CSU) and anticipates a BLA submission in 2027.

“Barzolvolimab has significant potential to address enormous populations of high unmet need and shift the treatment paradigm goal from symptom improvement to complete symptom resolution, which for patients means no itch, no hives, no swelling.”

Anthony Marucci, Co-founder, President and Chief Executive Officer

“This quarter we reported best-in-disease results from our two Phase 3 studies in CSU, demonstrating barzolvolimab’s unparalleled ability to deliver complete response to patients—including even in patient populations suffering with severe disease or severe angioedema or with omalizumab refractory disease.”

Anthony Marucci, Co-founder, President and Chief Executive Officer
4:02 PM ET 10-Q
Financial Results Ecovyst Inc. ECVT ▶ Call

Ecovyst Q3 2026 Results: Turns Profitable, Net Income $18.2M

Ecovyst Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $30.3 million compared to a net loss of $76.9 million in the prior year period. The improvement was driven by a 47.6% increase in sales to $773.6 million and the absence of the large $73.9 million loss from discontinued operations recorded in 2025.

Key figure
Net income $18.2M
4:01 PM ET 10-Q
Financial Results Unity Bancorp Inc UNTY

Unity Bancorp Q3 2026 Results: Net Income $17.4M, Up 20.8% YoY

Unity Bancorp reported net income of $17.4 million for the third quarter of 2026, an increase from $14.4 million in the prior year period, driven by higher net interest income. Total assets grew to $3.25 billion as of September 30, 2026, primarily due to significant growth in the commercial loan portfolio.

Key figure
Net income $17.4M · +20.8% YoY
4:01 PM ET 8-K
Financial Results Perdoceo Education Corp PRDO

Perdoceo Education Financial Results

Perdoceo Education reported Q3 2026 financial results with revenue increasing 1.9% to $215.9 million and diluted EPS growing 16.7% to $0.70. The company noted strong student retention and interest, while confirming its acquisition of South University remains on track to close as early as April 2027.

Term
Q3 2026

“Third quarter operating performance was ahead of our expectations, as our portfolio of academic institutions experienced strong prospective student interest and student retention trended near historical highs.”

Todd Nelson, President and Chief Executive Officer

“Importantly, we remain committed to investing in student support and technology that we believe will further enhance both student experiences and academic outcomes. Looking ahead, we are on track to complete our acquisition of South University as early as April 2027, and expect to continue generating long-term, sustainable and responsible growth.”

Todd Nelson, President and Chief Executive Officer
4:01 PM ET 8-K
Financial Results Expensify, Inc. EXFY

Expensify Financial Results

Expensify reported Q3 2026 revenue of $33.0 million and a net loss of $3.3 million, while generating $3.3 million in free cash flow. The company highlighted explosive growth in its 'New Expensify' platform, where revenue increased 212% year-over-year, and raised its full-year 2026 free cash flow guidance.

Term
Q3 2026

“Expensify Classic is a stable cash-flow engine whose customer base naturally declines over time, while New Expensify is our growth engine. That growth engine is taking on a massive, largely untapped market.”

David Barrett, Founder and CEO of Expensify
4:01 PM ET 8-K
Financial Results Unusual Machines, Inc. UMAC

Unusual Machines Financial Results

Unusual Machines reported Q3 2026 revenue of $13.9 million, a 551% increase year-over-year, driven by expansion in U.S. manufacturing and the acquisition of Upgrade Energy. Despite a GAAP net loss of $25 million primarily due to non-cash investment losses, the company maintained gross margins of 35.4% and reported a narrow adjusted EBITDA loss of $0.7 million.

Term
Q3 2026

“I am extremely encouraged by our relatively small adjusted EBITDA loss in a quarter where revenue does not yet reflect the benefits of our ongoing investments in growth. I continue to believe that Unusual Machines can achieve positive adjusted EBITDA in 2027 without compromising our growth plans.”

Allan Evans, CEO
4:01 PM ET 10-Q
Financial Results Heritage Global Inc. HGBL

Heritage Global Q3 2026 Results: Net Income $1.04M, Up 77.3% YoY

Heritage Global Inc. reported a net loss of $14.1 million for the nine months ended September 30, 2026, primarily driven by a $17.7 million loss from equity method investments. Despite the year-to-date loss, the company achieved a net income of $1.0 million in the third quarter of 2026, supported by growth in both services revenue and asset sales.

Key figure
Net income $1.04M · +77.3% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.